Sign Up
OverviewAPI
Adial Pharmaceuticals exercises warrants generating $3.5 million for general corporate, clinical, and regulatory activities linked to AD04, a therapy for AUD. H.C. Wainwright & Co. is the exclusive placement agent, with the offering closing by March 6, 2024.

Ask a question